Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
V.AFM: Record Fy2024 & Q4 ‘24 Tin Production Fy2025 Production Guidance Exploration Success (click to learn more) Noble Acquires Property with Significant Uranium, Rare Earth, Phosphorus & Silver Minerlaization (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Prime Medicine Inc PRME

Healthcare Biotechnology
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering the gene editing therapies to patients. It deploys its Prime Editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. It is engaged in developing Prime Editors as a new class of therapeutics with transformative potential to expand the application of curative precision genetic medicines. It has built a diversified portfolio of investigational therapeutic programs organized around core areas of focus, namely hematology and immunology, liver, lung, ocular and neuromuscular. The programs within its other areas of focus are on earlier stages of preclinical development and include Liver programs, such as Wilson's disease and glycogen storage disease 1b; Lung program, such as Cystic fibrosis; Ocular program, such as Retinitis pigmentosa caused by Rhodopsin mutations, and Neuromuscular programs, including Friedreich's ataxia and myotonic dystrophy type 1.


NDAQ:PRME - Post by User

Prime Medicine Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(303)
•••
  • whytestocksX
Post by whytestockson Apr 29, 2024 3:45pm
48 Views
Post# 36013319

Prime Medicine Announces FDA Clearance of Investigational Ne

Prime Medicine Announces FDA Clearance of Investigational Ne
NEWS: $PRME Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)First-Ever Open IND for Prime Editing Technology PM359 is Prime Medicine&#x2019;s Ex Vivo Product Candidate Designed to Correct a Prevalent Disease-Causing Mutation of CGD Initial Data Expected in 2025 CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, In...PRME - Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities